Panbela rises on positive DSMB feedback for cancer therapy study

Panbela Therapeutics

10/07/2023 14:19

** Shares of drug developer Panbela Therapeutics Inc
 PBLA.O  rise 5.6% to $2.27 premarket 
    ** Co says an independent Data Safety Monitoring Board
(DSMB) of the U.S. National Institutes of Health reviewed data
from an ongoing late-stage study testing its experimental
combination therapy targeting a type of pancreatic cancer 
    ** PBLA says the DSMB has recommended that the study
continue without modification 
    ** Says the DSMB identified no safety concerns for co's drug
candidate ivospemin in combination with chemotherapy -PBLA
    ** PBLA plans an interim analysis of the therapy in early
2024     
    ** Up to last close, stock was down 97.6% YTD 

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))